Intrinsic at the Annual Meeting of the German Society of Neurosurgery (DGNC)
June 16, 2012
Barricaid® Prosthesis for Anular Closure is an important thematic focal point of the 63rd Annual Meeting of the German Society of Neurosurgery. On June 16, 2012, 4 papers dealing with the clinical results of Barricaid were presented, which include, among others, 2-year results coming from a multinational clinical study.
Secure closure of the anular defect
Partial discectomy is a secure method for the treatment of intervertebral disc herniation. The risk of reherniation is, however, significant in certain patients with otherwise well preserved intervertebral discs and large defects, if the nucleus is not aggressively resected and the defect of the anulus fibrosis remains unclosed. Barricaid® has been developed by Intrinsic Therapeutics in order to prevent recurrent intervertebral disc herniations after the lumbar discectomy, in particular, in patients at high risk of recurrence. The prosthesis is the only product on the market that offers an alternative to conventional methods. Barricaid® has been constructed such that it blocks the anular defect, allowing most part of the nucleus to be left in the disc. The currently available data shows a substantial reduction in the reherniation rate compared to a control group, as well as better preservation of the intervertebral disc height.
Advantages confirmed in clinical use
The use of Barricaid® showed positive results during the current studies: a lower reherniation rate, even in cases of large anular defects, as well as a postoperative improvement in the VAS (Visual Analog Scale) and ODI (Oswestry Disability Index) patient outcome scores, and in the preservation of the intervertebral disc height. A possible explanation is that, apart from preventing the recurrence of an intervertebral disc herniation, the anular closure offers further advantages to the patient, with a positive effect on the outcome of the surgery.
About the Barricaid® prosthesis
The Barricaid® prosthesis for the closure of the anulus fibrosis helps surgeons to directly correct the defect in the region of the intervertebral disc herniation. By being implanted between the anulus and the nucleus, it forms a mechanical barrier. In consequence, more nucleus can be preserved between the intervertebral discs, and the risk of reherniation be reduced.
About Intrinsic Therapeutics
Intrinsic Therapeutics is headquartered in Woburn, Massachusetts. It is a company that concentrates on the development of innovative therapies, and addresses many unmet patient needs with vertebral spine problems. The company’s first product is Barricaid®, a revolutionary intervertebral disc implant which has been developed for the treatment of patients undergoing surgery due to lumbar intervertebral disc herniation.
For further information about Intrinsic Therapeutics, go to www.intrinsic-therapeutics.com